RNPA1000产品描述:RNPA1000 is an attractive antimicrobial development candidate; RnpA inhibitor.IC50 value:Target: RnpA inhibitorThe antibiotic vancomycin and a novel Staphylococcus aureus RnpA inhibitor under pre-clinical development, RNPA1000, were included in these studies. Rheological testing characterized the workability of the glass polyalkenoate cement over a range of powder-to-liquid ratios and polyacrylic acid concentrations and revealed that the most suitable powder-to-liquid ratio was 2/1.25 with 40 wt% polyacrylic acid. Loading glass polyalkenoate cement with either 20-30% RNPA1000 or vancomycin prevented bacterial growth. However, longer incubations allowed for Staphylococcus aureus colonies to form near the vancomycin-infused cement, indicating that vancomycin may not be suitable for long-term biofilm inhibition in comparison to RNPA1000. 公司介绍:MedChemExpress(MCE)专注于各种抑制剂、激动剂、API及化合物库,总部位于美国新泽西,分别在瑞典和上海设有欧洲区子公司和亚洲区总代理,营销网点遍及全球20多个国家地区。MCE经过多年努力已成为全球生物活性小分子领域的一流供应商, 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域,PI3K、MAPK等近千个细分靶点,超过4000个活性小分子化合物现货,以及GPCR、API、离子通道等超过20种不同类型的化合物库,同时提供从毫克到千克的专业定制合成服务。 MCE 对每批产品都进行严格的LCMS和NMR检验,其产品已被全球近万名客户广泛使用并发表大量文章、专利; MCE 定期增加各领域热门抑制剂、激动剂,不断扩增已有化合物库,以满足最新的科研需求; 数千种产品在上海有充足备货,24-48小时内送达客户; 大量产品提供免费试用装;已为全球多个知名企业、院校构建各种定制型化合物库。 产品链接:www.medchemexpress.cn/rnpa1000.html ![]() |
RNPA1000研究进展
发布日期:2017-11-01 浏览次数:0
核心提示:a href=https://www.medchemexpress.com/RNPA1000.htmlRNPA1000/a产品描述:RNPA1000 is an attractive antimicrobial developme
- 下一篇:TP-0903研究进展
- 上一篇:BLU9931研究进展
行业动态
更多...
- ATN-161 (trifluoroacetat 11-06
- AZM475271研究进展 11-06
- AVN-944研究进展 11-06
- Ascomycin研究进展 11-06
- β-Lapachone研究进展 11-06
- Anidulafungin研究进展 11-06
- Amsacrine (hydrochloride 11-06
- Amsacrine研究进展 11-06
- Uramustine研究进展 11-06
- Exherin (trifluoroacetat 11-06